Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations - Wikidata - wikimedia - TriplyDB

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

http://www.wikidata.org/entity/Q34503883

about

Fibulin-3 as a biomarker of response to treatment in malignant mesothelioma Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-naïve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenoc [F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients.Intercalated chemotherapy and erlotinib for non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations.Outcome of severe infections in afebrile neutropenic cancer patients.Evaluation of Safety and Efficacy of Salvage Therapy With Sunitinib, Docetaxel (Tyxan) and Cisplatinum Followed by Maintenance Vinorelbine for Unresectable/Metastatic Nonsmall Cell Lung Cancer: Stage 1 of a Simon 2 Stage Clinical Trial. [Corrected].Insulin-like Growth Factor 1 Receptor Expression in Advanced Non-small-cell Lung Cancer and its Impact on Overall Survival.Chemotherapy and intercalated gefitinib or erlotinib in the treatment of advanced non-small-cell lung cancer.Selection of Non-small Cell Lung Cancer Patients for Intercalated Chemotherapy and Tyrosine Kinase Inhibitors Upregulation of SALL4 by EGFR activation regulates the stemness of CD44-positive lung cancer.

P2860

Q28389185-67DF5B43-C872-4B1A-B3B3-89087F0FFD80 Q35817772-A2E6F6B0-28C3-46E3-AB1F-6D11AF3DFDDD Q36490370-31B0DBB6-D52F-463E-AFF2-48211D94EF0A Q37357699-A7F431F1-3060-4636-85E2-29ED9B4043D1 Q37432031-ADDBC3BF-0E37-47E7-B90F-B62113DFF400 Q37624187-B1EF0668-FF06-4569-927D-A3B16E1237EB Q38663388-CCD6EAE0-203F-42DA-9A98-10E82C5B4409 Q38983980-035E7CAA-1B05-46D1-995E-949F8E116A0C Q41678123-1799A3E0-31BB-48A2-B533-142310A96705 Q52565512-474922AF-A66C-40C0-A408-EFB895BEB1C7

P2860

Intercalated chemotherapy and erlotinib for advanced NSCLC: high proportion of complete remissions and prolonged progression-free survival among patients with EGFR activating mutations

http://www.wikidata.org/entity/Q34503883

description

2014 nî lūn-bûn

@nan

2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Intercalated chemotherapy and ...... with EGFR activating mutations

@ast

Intercalated chemotherapy and ...... with EGFR activating mutations

@en

Intercalated chemotherapy and ...... with EGFR activating mutations

@nl

type

label

Intercalated chemotherapy and ...... with EGFR activating mutations

@ast

Intercalated chemotherapy and ...... with EGFR activating mutations

@en

Intercalated chemotherapy and ...... with EGFR activating mutations

@nl

prefLabel

Intercalated chemotherapy and ...... with EGFR activating mutations

@ast

Intercalated chemotherapy and ...... with EGFR activating mutations

@en

Intercalated chemotherapy and ...... with EGFR activating mutations

@nl

P1433

Q34503883-C42F5DF3-22C5-4CAB-AE0A-76954E736178

P1476

Q34503883-694253DD-7462-44FC-88B3-515888F9E4C9

P2093

Q34503883-183E5F23-DC36-41DC-AE09-8F1FD61ED9DF

Q34503883-1E8D6FBF-982E-47C0-B7C1-E86902125CB2

Q34503883-3DCF1A58-4C10-4A0B-B994-38116804C676

Q34503883-9B768A4A-28C3-4722-8182-1860E791A534

Q34503883-D7ECE1C5-D2D7-4F77-B3D3-A08897851F82

Q34503883-DBD12BE9-19CC-44EE-92B0-757521EE2546

Q34503883-E94AF1C1-14EE-4845-8C34-33C2A9FC09C8

P2860

Q34503883-1864594D-8E85-4ADF-A014-09F05C3F21CF

Q34503883-189486EC-DDD0-45EB-B9A7-94ED64041BB0

Q34503883-209261EE-C3B3-46DD-B214-FD1C0067FB0E

Q34503883-2196014C-C00A-48B0-B099-4689DFD56243

Q34503883-29E2B253-C9ED-4EF8-A785-D7BA887F4542

Q34503883-2AE4D7F2-7D7E-4D77-A79B-2C5B538966E4

Q34503883-2CCC4A99-0914-4C6A-959F-0DFF932DC9C1

Q34503883-320E7A30-B446-4794-894A-AD3155DAA565

Q34503883-3393454E-EC34-4085-BD38-5C9C5B05A13F

Q34503883-33DCE7C7-160C-465F-81A1-AEE70647ADD7

P304

Q34503883-36525EF5-AAC4-4892-8450-9B3C8A745BCA

P31

Q34503883-AB2B61E5-EBF6-482A-B728-023CA973ACC9

P356

Q34503883-49D3070F-E595-42B3-9FCA-43412F10A77B

P433

Q34503883-89652DBD-6C9A-4B82-B35C-C7FF7E5D9AFB

P478

Q34503883-38296DB4-69AE-45B3-89C5-EFC9D394D593

P577

Q34503883-FE665A5B-70E5-4DC2-BCE0-ACDD3AC3A7CE

P5875

Q34503883-B1E6C454-B685-4270-9F31-E1C281B6E18A

P698

Q34503883-BB20164F-E022-4C98-B165-E66333A1D162

P921

Q34503883-29FDAA95-217E-4FCC-9C6B-40D505297879

P932

Q34503883-D8F03CF5-5358-4BDC-9702-DB061F7A3995

P356

P1433

Radiology and Oncology

P1476

Intercalated chemotherapy and ...... with EGFR activating mutations

@en

P2093

Izidor Kern

http://www.w3.org/2001/XMLSchema#string

Karmen Stanic

http://www.w3.org/2001/XMLSchema#string

Martina Vrankar

http://www.w3.org/2001/XMLSchema#string

Matjaz Zwitter

http://www.w3.org/2001/XMLSchema#string

Mirjana Rajer

http://www.w3.org/2001/XMLSchema#string

Natalija Edelbaher

http://www.w3.org/2001/XMLSchema#string

Viljem Kovac

http://www.w3.org/2001/XMLSchema#string

P2860

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Screening for epidermal growth factor receptor mutations in lung cancer

[Phase II trial of improved regimen with gemcitabine in patients with advanced non-small cell lung cancer].

Intercalated combination of chemotherapy and erlotinib for patients with advanced stage non-small-cell lung cancer (FASTACT-2): a randomised, double-blind trial.

Brain metastases in lung adenocarcinoma: impact of EGFR mutation status on incidence and survival.

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.

First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study.

P304

361-368

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2478/RAON-2014-0038

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

48

http://www.w3.org/2001/XMLSchema#string

P577

2014-11-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

269114936

http://www.w3.org/2001/XMLSchema#string

P698

25435849

http://www.w3.org/2001/XMLSchema#string

P921

P932

4230556

http://www.w3.org/2001/XMLSchema#string